Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is related to what is referred to as crystalline psilocybin.

More specifically, the patent covers methods of treating treatment-resistant depression through the use of crystalline psilocybin. The patent also covers the use of oral dosage forms of the psilocybin with an excipient, which in layman terms means the psilocybin can be used in oral dosage format with a bulking agent, which can boost stability or bioavailability.

Notably, the tech protected by this latest patent is being utilized in COMP360, the firms formulation of synthesized psilocybin it is currently investigating for treatment against treatment-resistant depression.

The patent is the fifth for the company in the US, and its tenth globally. The firm currently holds two patents in each of Hong Kong and the United Kingdom, and one in Germany. As per the company, the patents “enable [Compass] to continue to do the highest quality clinical research.”

Compass Pathways last traded at $30.23 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM

Compass Pathways To Start Phase II Trial For Psilocybin PTSD Therapy

Compass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II...

Wednesday, November 3, 2021, 09:52:00 AM

Compass Pathways Sees “Reduction In Depressive Symptom” In Phase IIb Psilocybin Clinical Trial

Compass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy...

Tuesday, November 9, 2021, 12:33:00 PM

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the...

Monday, June 28, 2021, 07:37:00 AM

Compass: Canaccord Reiterates $80 Price Target After Study Data

Earlier this month, Compass Pathways (Nasdaq: CMPS) announced positive topline results and its key findings...

Monday, November 22, 2021, 02:44:00 PM